Asthma Management Guidelines

Introduction to Asthma Treatment

The American College of Physicians recommends inhaled corticosteroids (ICS) delivered via metered-dose inhaler (MDI) with a spacer device as the preferred first-line controller therapy for mild to moderate persistent asthma, with short-acting beta2-agonists (SABA) as needed for symptom relief 1, 2

For mild intermittent asthma, no daily controller medication is required, and short-acting inhaled beta2-agonist (albuterol/salbutamol) should be prescribed as needed for symptom relief, according to the American Thoracic Society 1, 3
For mild persistent asthma, low-dose inhaled corticosteroids (up to 800 μg/day beclomethasone equivalent) are the preferred controller treatment, delivered via MDI with large volume spacer, as recommended by the National Asthma Education and Prevention Program 1, 2
For moderate persistent asthma, low-dose ICS plus long-acting beta2-agonist (LABA) combination is preferred, with fluticasone propionate/salmeterol combination inhalers being FDA-approved for this indication, according to the American College of Chest Physicians 1
For severe persistent asthma, high-dose ICS plus LABA combination is the preferred treatment, with consideration of high-potency ICS formulations to minimize number of actuations and potentially improve outcomes, as recommended by the European Respiratory Society 1, 4

The American Academy of Allergy, Asthma, and Immunology recommends starting with MDI for most patients as it is the preferred delivery system, with addition of large volume spacer if patient has difficulty with MDI coordination 2
Spacer devices reduce oropharyngeal deposition and improve lung delivery, particularly beneficial for patients who cannot coordinate actuation with inhalation, according to the American Thoracic Society 2, 3

For moderate to severe exacerbations, administer oxygen 40-60% to maintain saturation >90% (>95% in pregnancy or heart disease), and nebulized salbutamol 5 mg or terbutaline 10 mg every 20-30 minutes for three doses, as recommended by the National Asthma Education and Prevention Program 3, 6, 2
For life-threatening asthma, continue high-dose nebulized beta-agonists with oxygen, and add IV aminophylline 250 mg over 20 minutes if no response, according to the American College of Emergency Physicians 6, 2

The American Academy of Pediatrics recommends checking inhaler technique at every visit, as this is a primary cause of treatment failure, and teaching proper MDI technique and providing peak flow meter for objective monitoring 2
Provide written asthma action plan detailing when to increase treatment and when to seek emergency care, and instruct patients to rinse mouth with water after ICS use to reduce oral candidiasis risk, as recommended by the National Asthma Education and Prevention Program 2
Educate patients that ICS are controller medications requiring daily use, not rescue therapy, and explain that SABA use more than a few times weekly indicates need for controller therapy escalation, according to the American College of Physicians 1, 2